A panel of nine therapeutic agents was selected to reflect the major treatment modalities in breast cancer care: chemotherapeutic drugs (Docetaxel, Paclitaxel, Cisplatin, and Methotrexate), HER2-targeted tyrosine kinase inhibitors (Lapatinib and Neratinib), and endocrine therapies (Tamoxifen, Fulvestrant, and Anastrozole). This evidence concerns the gene ERBB2 and breast cancer.